Kringle Pharma Reports July Exercise Status of 16th Tranche Warrant

TOKYO, Aug 03 (Pulse News Wire) – Kringle Pharma,inc. (4884.T) reported the exercise status of its 16th tranche warrant (exercise price adjustment clause attached) allocated to EVO FUND for the month of July 2026.

The warrant was issued on August 01, 2025, with a total issuance of 17,000 warrants. In July, there were no exercised warrants, resulting in no delivery of shares. As of the end of July, the number of unexercised warrants stood at 2,100 out of 2,100 initially available.

The exercise ratio remained unchanged at 416 per warrant throughout the month. Additionally, as of June 30, 2026, the outstanding share count was 8,383,200, including self-held shares totaling 183. The company adhered to the listing regulations' exercise restrictions based on Article 434, maintaining compliance with the exercise rate limit.